15 patents
Utility
Inhibition of Reperfusion Injury with a PSD-95 Inhibitor
14 Sep 23
The peptide inhibitor of PSD-95, Tat-NR2B9c, and related peptides can inhibit reperfusion injury when administered before blood flow is restored.
Michael TYMIANSKI
Filed: 19 Feb 21
Utility
Combination Treatment of Stroke with Plasmin-cleavable PSD-95 Inhibitor and Reperfusion
4 May 23
The peptide inhibitor of PSD-95, Tat-NR2B9c, is cleaved by the serum protease, plasmin, inducible by thrombolytic agents.
Michael TYMIANSKI, Jonathan David GARMAN
Filed: 19 Feb 21
Utility
Plasmin-resistant Peptides for Treating Stroke and Related Conditions
23 Feb 23
The invention provides variants of a previously described active agent for treating stroke, Tat-NR2B9c, in which target binding characteristics are retained by inclusion of L-amino acids at the C-terminus and plasmin-resistance is conferred by inclusion of D-amino acids elsewhere.
Michael Tymianksi, Jonathan David Garman, Diana Mayor
Filed: 8 Jan 21
Utility
Therapy for Subarachnoid Hemorrhage and Ischemia
9 Jun 22
The application provides data from a clinical trial of a PSD-95 inhibitor in subjects undergoing endovascular repair of an aneurysm in or otherwise affecting the CNS.
Michael Tymianski
Filed: 11 Nov 21
Utility
Chloride Salt of TAT-NR2B9C
9 Jun 22
The present invention provides lyophilized formulations of active agents, particularly of TAT-NR2B9c, as chloride salts.
Jonathan David Garman
Filed: 8 Dec 21
Utility
Therapy for subarachnoid hemorrhage and ischemia
24 May 22
The application provides data from a clinical trial of a PSD-95 inhibitor in subjects undergoing endovascular repair of an aneurysm in or otherwise affecting the CNS.
Michael Tymianski
Filed: 11 Apr 19
Utility
Lyophilized Formulation of TAT-NR2B9C with Acetylation Scavenger
31 Mar 22
The present invention provides lyophilized formulations of active agents, particularly of TAT-NR2B9c including histidine, trehalose and lysine.
Jonathan David Garman, Frieder Hofmann
Filed: 13 Sep 21
Utility
Chloride salt of TAT-NR2B9C
8 Mar 22
The present invention provides lyophilized formulations of active agents, particularly of TAT-NR2B9c, as chloride salts.
Jonathan David Garman
Filed: 17 Jun 20
Utility
Combination Therapy for Ischemia
7 Oct 21
The invention provides a combination treatment for ischemia conditions in or otherwise affecting the CNS, such as stroke.
Michael Tymianski
Filed: 17 Feb 21
Utility
Combination therapy for ischemia
6 Apr 21
The invention provides a combination treatment for ischemia conditions in or otherwise affecting the CNS, such as stroke.
Michael Tymianski
Filed: 1 Aug 18
Utility
Prelyophilized, lyophilized and reconstituted formulations comprising TAT-NR2B9C with d-amino acids, histidine and trehalose
9 Feb 21
The present invention provides lyophilized formulations of active agents, particularly of TAT-NR2B9c.
Jonathan David Garman
Filed: 20 Feb 19
Utility
Chloride Salt of TAT-NR2B9C
9 Dec 20
The present invention provides lyophilized formulations of active agents, particularly of TAT-NR2B9c, as chloride salts.
Jonathan David Garman
Filed: 16 Jun 20
Utility
Chloride salt of TAT-NR2B9c
31 Aug 20
The present invention provides lyophilized formulations of active agents, particularly of TAT-NR2B9c, as chloride salts.
Jonathan David Garman
Filed: 10 Sep 18
Utility
Method of Reducing Injury to Mammalian Cells
15 Jul 20
A method of inhibiting the binding between N-methyl-D-aspartate receptors and neuronal proteins in a neuron is disclosed.
Michael Tymianski
Filed: 20 Sep 19
Utility
Therapy for Subarachnoid Hemorrhage and Ischemia
22 Apr 20
The application provides data from a clinical trial of a PSD-95 inhibitor in subjects undergoing endovascular repair of an aneurysm in or otherwise affecting the CNS.
Michael Tymianski, Jonathan David Garman
Filed: 10 Apr 19
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first